Our best chance to fight CV is to create a vaccine as soon as possible. The irony is that we probably already have a vaccine but we can’t prove that it works, until animal safety test, 1 and 2 stage of the clinical trials, which will take 12-18 months at least. How we could accelerate the creation of the vaccine?

There are several ideas, which are mostly inspired by the research of anti-aging drugs, which suffer from the same problem: the need for very long clinical trials. See More Dakka post by Sara Constantin. 

  1. Immediate human trials. If we have the vaccine in 3 months, not 18 months, we will save millions of lives. So, based on the trolley problem logic, we may risk the health of a few thousand people to achieve these goals, especially if they were volunteers. Thus we need to start a human test of the vaccine candidates immediately, even before the end of animal trials, which are still needed. here we get acceleration by performing in parallel the actions which are typically done sequentially.
  2. Test safety and efficiency simultaneously. We also should combine 1 stage and 2 stages oа tests, that is safety and efficiency, by giving the vaccine to people who are already under potential exposure to CV, like nurses, or old people in nurseries. 
  3. Test on large groups. We should test a vaccine on a large group of people, like 10 000, so any finding will quickly get statistical significance. If the number of infection will decline relative to the control group, we could see it in one month.
  4. Test all vaccine candidates. All said above in 1-3 should be done with each of a dozen vaccine-candidates which are currently under developing. As a result, in one month we could know which vaccine candidate is the strongest and safest. 
  5. Manufacturing in advance. Simultaneously, we should start large scale production of all vaccine-candidates, if it is possible. After the best (maybe 3 or 5) vaccine-candidates are validated, the stockpile of failed vaccine-candidates is destroyed, and the best vaccines are delivered to the population. This will help to fight the production delay.
  6. Give people different best vaccines. There is still could be long-term detrimental effects of some of the vaccines, so it may be better not to give everybody just one best vaccine - what if it makes everybody will become sterile in 1 year?
  7. Combine best vaccines. To increase protection, we could give each person a combination of several (but not all to ensure point 6) of the best vaccines. Here I assume that detrimental interaction between vaccines is typically unlikely, but more technical analysis is needed. 
  8. Establish biomarkers of a good vaccine (e.g. antibodies). Biomarkers are important to check efficiency of a clinical trial before the final outcome is known.
  9. Try other approaches, like DRACO, distancing, coconut oil, a large dose of vitamin C etc and test them in the same accelerated way.

Several human trials already started: In China military volunteers are testing an experimental vaccine, and there are clinical trials of Moderna vaccine in the US.

10

0
0

Reactions

0
0

More posts like this

Comments3


Sorted by Click to highlight new comments since:

Have some of these ideas been brought up with relevant regulatory agencies? Have any of those agencies formally declared their unwillingness to relax standards in these cases?

Given all the unusual actions being taken around COVID, I'd be a bit surprised if these options were really off the table, or if the relevant agencies weren't considering many of them.

As I understand it, the Moderna human trial should have safety data good enough for real-world purposes in about two months. It's a test of 45 people, so if 7% of the population is infected by that time (as seems likely) and none of the vaccinated people are, that's p<0.05 that it's effective, even though they weren't deliberately testing that.

Granted, the vaccine might *not* work, in which case we need a different angle.

But if it does, the FDA will then delay it another year or two. Does anyone know of any leverage at all that could be exerted over the FDA?

There is a new animal in the room: private pay-to-play clinical trials in third countries. In one case, people have to pay 1 million USD to enrol into an anti-aging clinical trial. Some of them could be scams. But it an option to take the risk and get the vaccine earlier for customers, and to get volunteers for the company.

EDITED: Andre Watson will be now live about private vaccine creation: https://www.facebook.com/events/516073069307382/

Curated and popular this week
 ·  · 12m read
 · 
Economic growth is a unique field, because it is relevant to both the global development side of EA and the AI side of EA. Global development policy can be informed by models that offer helpful diagnostics into the drivers of growth, while growth models can also inform us about how AI progress will affect society. My friend asked me to create a growth theory reading list for an average EA who is interested in applying growth theory to EA concerns. This is my list. (It's shorter and more balanced between AI/GHD than this list) I hope it helps anyone who wants to dig into growth questions themselves. These papers require a fair amount of mathematical maturity. If you don't feel confident about your math, I encourage you to start with Jones 2016 to get a really strong grounding in the facts of growth, with some explanations in words for how growth economists think about fitting them into theories. Basics of growth These two papers cover the foundations of growth theory. They aren't strictly essential for understanding the other papers, but they're helpful and likely where you should start if you have no background in growth. Jones 2016 Sociologically, growth theory is all about finding facts that beg to be explained. For half a century, growth theory was almost singularly oriented around explaining the "Kaldor facts" of growth. These facts organize what theories are entertained, even though they cannot actually validate a theory – after all, a totally incorrect theory could arrive at the right answer by chance. In this way, growth theorists are engaged in detective work; they try to piece together the stories that make sense given the facts, making leaps when they have to. This places the facts of growth squarely in the center of theorizing, and Jones 2016 is the most comprehensive treatment of those facts, with accessible descriptions of how growth models try to represent those facts. You will notice that I recommend more than a few papers by Chad Jones in this
LintzA
 ·  · 15m read
 · 
Introduction Several developments over the past few months should cause you to re-evaluate what you are doing. These include: 1. Updates toward short timelines 2. The Trump presidency 3. The o1 (inference-time compute scaling) paradigm 4. Deepseek 5. Stargate/AI datacenter spending 6. Increased internal deployment 7. Absence of AI x-risk/safety considerations in mainstream AI discourse Taken together, these are enough to render many existing AI governance strategies obsolete (and probably some technical safety strategies too). There's a good chance we're entering crunch time and that should absolutely affect your theory of change and what you plan to work on. In this piece I try to give a quick summary of these developments and think through the broader implications these have for AI safety. At the end of the piece I give some quick initial thoughts on how these developments affect what safety-concerned folks should be prioritizing. These are early days and I expect many of my takes will shift, look forward to discussing in the comments!  Implications of recent developments Updates toward short timelines There’s general agreement that timelines are likely to be far shorter than most expected. Both Sam Altman and Dario Amodei have recently said they expect AGI within the next 3 years. Anecdotally, nearly everyone I know or have heard of who was expecting longer timelines has updated significantly toward short timelines (<5 years). E.g. Ajeya’s median estimate is that 99% of fully-remote jobs will be automatable in roughly 6-8 years, 5+ years earlier than her 2023 estimate. On a quick look, prediction markets seem to have shifted to short timelines (e.g. Metaculus[1] & Manifold appear to have roughly 2030 median timelines to AGI, though haven’t moved dramatically in recent months). We’ve consistently seen performance on benchmarks far exceed what most predicted. Most recently, Epoch was surprised to see OpenAI’s o3 model achieve 25% on its Frontier Math
Omnizoid
 ·  · 5m read
 · 
Edit 1/29: Funding is back, baby!  Crossposted from my blog.   (This could end up being the most important thing I’ve ever written. Please like and restack it—if you have a big blog, please write about it). A mother holds her sick baby to her chest. She knows he doesn’t have long to live. She hears him coughing—those body-wracking coughs—that expel mucus and phlegm, leaving him desperately gasping for air. He is just a few months old. And yet that’s how old he will be when he dies. The aforementioned scene is likely to become increasingly common in the coming years. Fortunately, there is still hope. Trump recently signed an executive order shutting off almost all foreign aid. Most terrifyingly, this included shutting off the PEPFAR program—the single most successful foreign aid program in my lifetime. PEPFAR provides treatment and prevention of HIV and AIDS—it has saved about 25 million people since its implementation in 2001, despite only taking less than 0.1% of the federal budget. Every single day that it is operative, PEPFAR supports: > * More than 222,000 people on treatment in the program collecting ARVs to stay healthy; > * More than 224,000 HIV tests, newly diagnosing 4,374 people with HIV – 10% of whom are pregnant women attending antenatal clinic visits; > * Services for 17,695 orphans and vulnerable children impacted by HIV; > * 7,163 cervical cancer screenings, newly diagnosing 363 women with cervical cancer or pre-cancerous lesions, and treating 324 women with positive cervical cancer results; > * Care and support for 3,618 women experiencing gender-based violence, including 779 women who experienced sexual violence. The most important thing PEPFAR does is provide life-saving anti-retroviral treatments to millions of victims of HIV. More than 20 million people living with HIV globally depend on daily anti-retrovirals, including over half a million children. These children, facing a deadly illness in desperately poor countries, are now going
Relevant opportunities
27
CEEALAR
· · 1m read